Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Nila U"'
Autor:
Farshid Dayyani, Nila U Parikh, Andreas S Varkaris, Jian H Song, Shhyam Moorthy, Tanushree Chatterji, Sankar N Maity, Adam R Wolfe, Joan M Carboni, Marco M Gottardis, Christopher J Logothetis, Gary E Gallick
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e51189 (2012)
Treatment of metastatic prostate cancer (PCa) with single agents has shown only modest efficacy. We hypothesized dual inhibition of different pathways in PCa results in improved tumor inhibition. The Src family kinases (SFK) and insulin-like growth f
Externí odkaz:
https://doaj.org/article/c465cfc0adbb4c2a939a2056b7b01849
Autor:
Sue-Hwa Lin, Gary E. Gallick, Li-Yuan Yu-Lee, Robert L. Satcher, Christopher Logothetis, Paul Corn, Andreas Varkaris, Nila U. Parikh, David H. Hawke, Hsuan-Chen Liu, Bin Liu, Chien-Jui Cheng, Guoyu Yu, Song-Chang Lin, Yu-Chen Lee
Tumor recurrence after discontinuation of cabozantinib treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64b6cdd9e7826852a2afe5ee4d3f470c
https://doi.org/10.1158/0008-5472.22410338.v1
https://doi.org/10.1158/0008-5472.22410338.v1
Autor:
Scott Kopetz, Gary E. Gallick, Alain R. Thierry, Michael J. Overman, Cathy Eng, Robert A. Wolff, David G. Menter, Anastasia D. Katsiampoura, David R. Fogelman, Arvind Dasari, Kanwal Raghav, Marc Ychou, Brice Pastor, Feng Tian, Laura Henderson, Zhi-Qin Jiang, Ji Yuan Wu, Nila U. Parikh, Christine M. Parseghian
Purpose: Aberrant activation of the intracellular tyrosine kinase Src has been implicated as a mechanism of acquired chemotherapy resistance in metastatic colorectal cancer (mCRC). Here, the oral tyrosine kinase Src inhibitor, dasatinib, was investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::493cba9094cd2e6c43821d133756c6a5
https://doi.org/10.1158/1078-0432.c.6526826
https://doi.org/10.1158/1078-0432.c.6526826
Autor:
Gary E. Gallick, Christopher J. Logothetis, Sue-Hwa Lin, Mian Alauddin, Yiping Shao, Bogdan A. Czerniak, Menashe Bar Eli, Sankar N. Maity, Lynnelle Thorpe, Sanchaika Gaur, Anh G. Hoang, Ana Aparicio, Yu-Chen Lee, Jian H. Song, Eleni Efstathiou, Nila U. Parikh, Paul G. Corn, Andreas Varkaris
Supplemental Figure 1 (fig. S1). Representative whole body NaF-18 PET scan images after 44 days of (A) vehicle-treated and (B) cabozantinib-treated animals. Supplemental Figure 2 (fig. S2). Effect of cabozantinib on PDX tumor growth, animal weight, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1771a12684127acc4701f3e4133b4f8d
https://doi.org/10.1158/1078-0432.22461362
https://doi.org/10.1158/1078-0432.22461362
Autor:
Sue-Hwa Lin, Gary E. Gallick, Li-Yuan Yu-Lee, Robert L. Satcher, Christopher Logothetis, Paul Corn, Andreas Varkaris, Nila U. Parikh, David H. Hawke, Hsuan-Chen Liu, Bin Liu, Chien-Jui Cheng, Guoyu Yu, Song-Chang Lin, Yu-Chen Lee
Resistance to currently available targeted therapies significantly hampers the survival of patients with prostate cancer with bone metastasis. Here we demonstrate an important resistance mechanism initiated from tumor-induced bone. Studies using an o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7fcf6d0630510ec6459c7cfd3016f8d
https://doi.org/10.1158/0008-5472.c.6507965
https://doi.org/10.1158/0008-5472.c.6507965
Autor:
Scott Kopetz, Gary E. Gallick, Alain R. Thierry, Michael J. Overman, Cathy Eng, Robert A. Wolff, David G. Menter, Anastasia D. Katsiampoura, David R. Fogelman, Arvind Dasari, Kanwal Raghav, Marc Ychou, Brice Pastor, Feng Tian, Laura Henderson, Zhi-Qin Jiang, Ji Yuan Wu, Nila U. Parikh, Christine M. Parseghian
Validation of peripheral blood mononuclear cells as a biomarker of Src inhibition. Freshly collected peripheral blood mononuclear cells from a healthy volunteer were treated ex-vivo with dasatinib 300 nM or hydrogen peroxide 0.05 mM. The peripheral b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42048aa738ec1b6e17d9bcc70397504b
https://doi.org/10.1158/1078-0432.22468073
https://doi.org/10.1158/1078-0432.22468073
Autor:
Gary E. Gallick, Christopher J. Logothetis, Sue-Hwa Lin, Mian Alauddin, Yiping Shao, Bogdan A. Czerniak, Menashe Bar Eli, Sankar N. Maity, Lynnelle Thorpe, Sanchaika Gaur, Anh G. Hoang, Ana Aparicio, Yu-Chen Lee, Jian H. Song, Eleni Efstathiou, Nila U. Parikh, Paul G. Corn, Andreas Varkaris
Purpose: We performed parallel investigations in cabozantinib-treated patients in a phase II trial and simultaneously in patient-derived xenograft (PDX) models to better understand the roles of MET and VEGFR2 as targets for prostate cancer therapy.Ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f627afa09d75e41a7e6ac87ed12b9c4
https://doi.org/10.1158/1078-0432.c.6524774
https://doi.org/10.1158/1078-0432.c.6524774
Autor:
Scott Kopetz, Gary E. Gallick, Alain R. Thierry, Michael J. Overman, Cathy Eng, Robert A. Wolff, David G. Menter, Anastasia D. Katsiampoura, David R. Fogelman, Arvind Dasari, Kanwal Raghav, Marc Ychou, Brice Pastor, Feng Tian, Laura Henderson, Zhi-Qin Jiang, Ji Yuan Wu, Nila U. Parikh, Christine M. Parseghian
Operating characteristics. A summary of the probability of stopping the trial early for the indicated true response rates.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1507020a7c8559fc408126becd09af
https://doi.org/10.1158/1078-0432.22468061
https://doi.org/10.1158/1078-0432.22468061
Autor:
Scott Kopetz, Gary E. Gallick, Alain R. Thierry, Michael J. Overman, Cathy Eng, Robert A. Wolff, David G. Menter, Anastasia D. Katsiampoura, David R. Fogelman, Arvind Dasari, Kanwal Raghav, Marc Ychou, Brice Pastor, Feng Tian, Laura Henderson, Zhi-Qin Jiang, Ji Yuan Wu, Nila U. Parikh, Christine M. Parseghian
Supplemental material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39aa0ab58191ff5a8d7e882c49b26d1e
https://doi.org/10.1158/1078-0432.22468064.v1
https://doi.org/10.1158/1078-0432.22468064.v1
Autor:
Scott Kopetz, Gary E. Gallick, Alain R. Thierry, Michael J. Overman, Cathy Eng, Robert A. Wolff, David G. Menter, Anastasia D. Katsiampoura, David R. Fogelman, Arvind Dasari, Kanwal Raghav, Marc Ychou, Brice Pastor, Feng Tian, Laura Henderson, Zhi-Qin Jiang, Ji Yuan Wu, Nila U. Parikh, Christine M. Parseghian
Lack of correlation between Src activity in PBMCs and hepatic tumors. For the patients in the expansion cohort, the change in the expression of pSrc and total Src was not correlated with a change in the phosphorlyation of the Src substrate paxillin.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5672206e4a57e3878ce7df721ab8dd75
https://doi.org/10.1158/1078-0432.22468070
https://doi.org/10.1158/1078-0432.22468070